Skip to Main Content

Paper Details

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Ann Oncol
93
2022
HER2, HER2+, HER2+ breast cancer, HER2+ metastatic breast cancer, HER2CLIMB, Patients, Tucatinib, brain metastases, capecitabine, human epidermal, human epidermal growth factor receptor 2, metastatic breast cancer, patient, patients, trastuzumab, tucatinib
Author NameAffiliation
Giuseppe CuriglianoIstituto Europeo di Oncologia, IRCCS and University of Milano
Lisa A CareyUNC Lineberger Comprehensive Cancer Center
Gabriel N HortobagyiMD Anderson Cancer Center
Ian E KropDana-Farber Cancer Institute
Dennis J SlamonUniversity of California, Los Angeles/Jonsson Comprehensive Cancer Center
Eric P WinerDana-Farber Cancer Institute
  • 1 - 6

Datasets

Release 1.2